156 related articles for article (PubMed ID: 12399198)
21. Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice.
Rafati S; Ghaemimanesh F; Zahedifard F
Vaccine; 2006 Apr; 24(16):3290-7. PubMed ID: 16481076
[TBL] [Abstract][Full Text] [Related]
22. DNA-protein immunization using Leishmania peroxidoxin-1 induces a strong CD4+ T cell response and partially protects mice from cutaneous leishmaniasis: role of fusion murine granulocyte-macrophage colony-stimulating factor DNA adjuvant.
Bayih AG; Daifalla NS; Gedamu L
PLoS Negl Trop Dis; 2014 Dec; 8(12):e3391. PubMed ID: 25500571
[TBL] [Abstract][Full Text] [Related]
23. Vaccination of BALB/c mice with Leishmania major amastigote-specific cysteine proteinase.
Rafati S; Baba AA; Bakhshayesh M; Vafa M
Clin Exp Immunol; 2000 Apr; 120(1):134-8. PubMed ID: 10759774
[TBL] [Abstract][Full Text] [Related]
24. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.
Campbell SA; Alawa J; Doro B; Henriquez FL; Roberts CW; Nok A; Alawa CB; Alsaadi M; Mullen AB; Carter KC
Vaccine; 2012 Feb; 30(7):1357-63. PubMed ID: 22210224
[TBL] [Abstract][Full Text] [Related]
25. Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infection.
Tabbara KS; Peters NC; Afrin F; Mendez S; Bertholet S; Belkaid Y; Sacks DL
Infect Immun; 2005 Aug; 73(8):4714-22. PubMed ID: 16040984
[TBL] [Abstract][Full Text] [Related]
26. Enhancement of immune response induced by DNA vaccine cocktail expressing complete LACK and TSA genes against Leishmania major.
Ghaffarifar F; Jorjani O; Sharifi Z; Dalimi A; Hassan ZM; Tabatabaie F; Khoshzaban F; Hezarjaribi HZ
APMIS; 2013 Apr; 121(4):290-8. PubMed ID: 23030526
[TBL] [Abstract][Full Text] [Related]
27. DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice.
López-Fuertes L; Pérez-Jiménez E; Vila-Coro AJ; Sack F; Moreno S; Konig SA; Junghans C; Wittig B; Timón M; Esteban M
Vaccine; 2002 Dec; 21(3-4):247-57. PubMed ID: 12450700
[TBL] [Abstract][Full Text] [Related]
28. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major.
Rafati S; Salmanian AH; Taheri T; Vafa M; Fasel N
Vaccine; 2001 May; 19(25-26):3369-75. PubMed ID: 11348700
[TBL] [Abstract][Full Text] [Related]
29. Vaccination with DNA encoding internal proteins of influenza virus does not require CD8(+) cytotoxic T lymphocytes: either CD4(+) or CD8(+) T cells can promote survival and recovery after challenge.
Epstein SL; Stack A; Misplon JA; Lo CY; Mostowski H; Bennink J; Subbarao K
Int Immunol; 2000 Jan; 12(1):91-101. PubMed ID: 10607754
[TBL] [Abstract][Full Text] [Related]
30. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease.
Campos-Neto A; Porrozzi R; Greeson K; Coler RN; Webb JR; Seiky YA; Reed SG; Grimaldi G
Infect Immun; 2001 Jun; 69(6):4103-8. PubMed ID: 11349082
[TBL] [Abstract][Full Text] [Related]
31. Interferon-gamma-inducing oral vaccination with Leishmania amazonensis antigens protects BALB/c and C57BL/6 mice against cutaneous leishmaniasis.
Pinto EF; de Mello Cortezia M; Rossi-Bergmann B
Vaccine; 2003 Sep; 21(25-26):3534-41. PubMed ID: 12922080
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.
Abdian N; Gholami E; Zahedifard F; Safaee N; Rafati S
Exp Parasitol; 2011 Mar; 127(3):627-36. PubMed ID: 21187087
[TBL] [Abstract][Full Text] [Related]
33. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.
Bhowmick S; Ravindran R; Ali N
Infect Immun; 2008 Mar; 76(3):1003-15. PubMed ID: 18195029
[TBL] [Abstract][Full Text] [Related]
34. Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens.
Berberich C; Ramírez-Pineda JR; Hambrecht C; Alber G; Skeiky YA; Moll H
J Immunol; 2003 Mar; 170(6):3171-9. PubMed ID: 12626575
[TBL] [Abstract][Full Text] [Related]
35. Vaccination of the Leishmania major susceptible BALB/c mouse. I. The precise selection of peptide determinant influences CD4+ T cell subset expression.
Soares LR; Sercarz EE; Miller A
Int Immunol; 1994 May; 6(5):785-94. PubMed ID: 7521670
[TBL] [Abstract][Full Text] [Related]
36. Transitory or long-lasting immunity to Leishmania major infection: the result of immunogenicity and multicomponent properties of histone DNA vaccines.
Carrión J; Folgueira C; Alonso C
Vaccine; 2008 Feb; 26(9):1155-65. PubMed ID: 18255202
[TBL] [Abstract][Full Text] [Related]
37. DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB/c mice.
Ahmed SB; Touihri L; Chtourou Y; Dellagi K; Bahloul C
Vaccine; 2009 Jan; 27(1):99-106. PubMed ID: 18951941
[TBL] [Abstract][Full Text] [Related]
38. Early CD44(hi)CD4+ and CD44(hi)CD8+ T cell numbers and the absence of mannose-rich glycoconjugates determine the protective outcome of anti-leishmanial immunity.
Kedzierski L; Curtis JM; Kedzierska K
Parasitology; 2009 Jul; 136(8):833-40. PubMed ID: 19490731
[TBL] [Abstract][Full Text] [Related]
39. Protective immune responses induced by vaccination with an expression genomic library of Leishmania major.
Piedrafita D; Xu D; Hunter D; Harrison RA; Liew FY
J Immunol; 1999 Aug; 163(3):1467-72. PubMed ID: 10415048
[TBL] [Abstract][Full Text] [Related]
40. DNA vaccination with a plasmid encoding LACK-TSA fusion against Leishmania major infection in BALB/c mice.
Maspi N; Ghaffarifar F; Sharifi Z; Dalimi A; Khademi SZ
Malays J Pathol; 2017 Dec; 39(3):267-275. PubMed ID: 29279589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
